CD28-costimulated autologous peripheral blood T-cells
Ovarian, Fallopian Tube and Peritoneal Cancer
Abramson Cancer Center at Penn MedicinePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
52 Active assets in the Ovarian, Fallopian Tube and Peritoneal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 AstraZeneca | Phase 2 | BB |
Carboplatin AbbVie | Phase 2/3 | BB |
Indocyanine Green Istanbul University | Phase 4 | BB |
Ringer's acetate Joachim Zdolsek | Phase 4 | B |
Nivolumab Clovis Oncology, Inc. | Phase 2 | B |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →